First Application of Haselmeier’s Axis-D Injection Pen is Launched

| Print |
Monday, 19 September 2011 13:00 (UTC + 2)

Haselmeier_Logo

Zurich, Switzerland, September 19, 2011 / B3C newswire / - Haselmeier has announced that the first application of its Axis-D pen platform has been launched. Commissioned by its client Merck Serono, a division of Merck KGaA, Germany, the new injection device has been designed to allow self injection by patients of a ready to use biopharmaceutical solution for injection.

“With the Axis pen platform it is easy to tailor the injection device to various needs. Following our client’s specifications, we have developed a device that enables users to adjust the volume of the injection and reuse the pen several times until the cartridge is empty. For security reasons, we added a function to the pen to immediately confirm that a complete dose was delivered, or to indicate the missing amount if an incomplete dose is injected,” said Volker Wirth, Director Business Development & Marketing at Haselmeier. “We are proud of this successful collaboration with Merck Serono and we look forward to continuing our business relationship in the future.”

The Axis pen platform is available as a reusable or disposable multi-use pen which features adjustable dosing. The pen design is based on an innovative technology featuring a sliding dose window which allows easy reading of the dose and provides reduced risk of incorrect dosing. Available in metal or plastic, the Axis pen is compatible with 3ml cartridges, all fill volumes and can be customized to meet any patient needs.


About Haselmeier GmbH
Haselmeier is a leading designer and manufacturer of pen and auto-injection systems. The Company’s devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. For more information visit: www.Haselmeier.com


Contact
Haselmeier GmbH
Nadia Di Secli
Dufourstr. 32
CH-8008 Zürich
Switzerland
Tel.: + 41 44 250 52 40
This e-mail address is being protected from spambots. You need JavaScript enabled to view it